|
|}
'''Opicaponum''' (abbreviatura: '''OPC''') est [[medicamentum pharmaceuticum]] imprimis [[neurologia]]e inad [[morbus Parkinson|morbomorbum Parkinson]] tractandotractandum adhibitum. Substantia gregi [[inhibitor catechol-O-methyltransferasis|inhibitorum COMT]] attribuitur, quod estsignificat, ut enzymum COMT ([[catechol-O-methyltransferasis]]) inhibiturinhiberetur. PraeEffectus aliisOpicaponi gregumlongiores horumaliorum effectussubstantiorum Opicaponihuius longiusgregis sunt.
Adhuc aliqui hepatotoxici effectus [[Tolcaponum|Tolcaponi]] incogniti sunt<ref name="SCOTT16">{{cite journal |authors=Scott L. J. |title=Opicapone: A Review in Parkinson's Disease |journal=Drugs |year=2016 |month=Sep |volume=76 |issue=13 |pages=1293-1300 |url=https://www.ncbi.nlm.nih.gov/pubmed/27498199/}}</ref>.
== Natura Opicaponi ==
Opicaponum est derivatum chemicum [[oxadiazolum|oxadiazoli]]. Nomen chemicum ([[IUPAC]]) est (4E)-4-[3-(2,5-dichloro-4,6-dimethyl-1-oxido-pyridin-1-ium-3-yl)-2H-1,2,4-[[oxadiazolum|oxadiazol]]-5-ylidum]-2-hydroxy-6-nitrocyclohexa-2,5-dien-1-onum. [[Massa molaris]] est 413.17 g/mol.
Solubilitas in [[aqua]] 1,2,4-oxadiazolooxadiazoli causa bene est, et ob appendicem N-oxidi pyridini toxicitas cellularum (prae [[Tolcaponum|Tolcapono]]) parva et obssessioobsessio enzymi COMT magna<ref>{{cite journal |authors=Kiss L. E., Ferreira H. S., Torrão L., Bonifácio M. J., Palma P. N., Soares-da-Silva P., Learmonth D. A. |title=Discovery of a long-acting, peripherally selective inhibitor of catechol-O-methyltransferase |journal=Journal of medicinal chemistry |year=2010 |month=Apr |volume=53 |issue=8 |pages=3396-411 |url=https://www.ncbi.nlm.nih.gov/pubmed/20334432/}}</ref>.
<gallery>
=== Natura pharmacologica ===
Opicaponum est inhibitor enzymi COMT. Per haec adhibeturPropterea in [[morbus Parkinson|morbo Parkinson]] tractando adhibetur. [[Systema classificationis Anatomicum Therapeuticum Chemicumque|Codex ATC]] est {{ATC|N04BX|04}}.
=== Pharmacodynamica ===
Opicaponum enzymum inhibit. Effectus Opicaponi simul selectivi et reversibiles sunt. Spatium effectuum dosis singularis plus quam 24 horas permanentest.
=== Pharmacocinetica ===
== Effectus Opicaponi ==
=== Effectus pharmacologici ===
Ut supra scriptum Opicaponum enzymum COMT inhibet. DeminutioneDeminutionis degradationis causa neurotransmissoris DOPA, eventuscausa incrementum neurotransmissoris praesynaptici fit.
Praeter desiderabiles cum uso Opicaponi animum advertere ad effectus secundarios et interactiones necesse est.
==== Effectus secundarii ====
==== Interactiones ====
== Usus medicusmedicinus ==
Quamquam [[tempus semivitae biologicum]] eius valde breve est, prae aliis inhibtoribusinhibitoribus COMT ut [[Entacaponum|Entacapono]] vel [[Tolcaponum|Tolcapono]] spatium effectuum longius sustinetur, paene viginti quattuor horae<ref>{{cite journal |authors=Rocha J. F., Almeida L., Falcão A., Palma P. N., Loureiro A. I., Pinto R., Bonifácio M. J., Wright L. C., Nunes T., Soares-da-Silva P. |title=Opicapone: a short lived and very long acting novel catechol-O-methyltransferase inhibitor following multiple dose administration in healthy subjects |journal=British journal of clinical pharmacology |year=2013 |month=Nov |volume=76 |issue=5 |pages=763-75 |url=https://www.ncbi.nlm.nih.gov/pubmed/23336248}}</ref>.
Dosis 50 mg Opicaponi vesperivespere<ref name="SCOTT16" /> cum intervallo minimo unae horae ab L-DOPA commendata est.
== Notae ==
| 